Moderna, Inc. (MRNA)

Close Price	Market Cap	P/E Ratio	Forward P/E Ratio	Implied Growth*	Implied Forward Growth*	Dividend	P/B Ratio
$47.19	$18.72B	-	-11.2	N/A	-	-	2.1

Latest Headlines

· JPMorgan says large-cap biotech is back as profits and pipelines fuel upside
· This Biotech Stock Is Stuck in the Red. Its Cancer Portfolio Is About to Change the Narrative.
· Astellas eyes more cost cuts; FDA panel to debate Moderna vaccine
· Litigation Windfall Driving Roivant Sciences’ Profit Swing Might Change The Case For Investing In Roivant Sciences (ROIV)
· 3 Cash-Burning Stocks with Open Questions
· Moderna (MRNA) Is Down 5.5% After FDA Sets Flu Vaccine Review, Tightens Lawsuit Venue Rules - What's Changed

Revenue & Net Income

	Date	Revenue	Net_Income	EPS	Last_Updated	Revenue_Change	Net_Income_Change	EPS_Change
0	2020-12-31	$274M	$-747M	$-1.96	2024-02-03 03:17:10	N/A	N/A	N/A
1	2021-12-31	$18,875M	$8,362M	$30.31	2026-05-29 09:11:54	6788.7%	-1219.4%	-1646.4%
2	2022-12-31	$18,875M	$8,362M	$21.26	2026-05-29 09:11:54	0.0%	0.0%	-29.9%
3	2023-12-31	$6,754M	$-4,714M	$-12.33	2026-05-29 09:11:54	-64.2%	-156.4%	-158.0%
4	2024-12-31	$3,199M	$-3,561M	$-9.28	2026-05-29 09:11:54	-52.6%	-24.5%	-24.7%
5	2025-12-31	$1,922M	$-2,822M	$-9.28	2026-05-29 09:11:54	-39.9%	-20.8%	0.0%
6	TTM 2026-03-31	$2,204M	$-3,194M	$-8.14	2026-05-05 08:51:33	14.7%	13.2%	-12.3%

EPS

Forecasts

Y/Y % Change

YoY Growth Rates

MRNA Year-over-Year Growth

	2020	2021	2022	2023	2024	2025	2026	2027	Average
Revenue Growth (%)		6788.7%	0.0%	-64.2%	-52.6%	-39.9%	8.6%	20.4%	951.6%
Revenue Analysts (#)	0	0	0	0	0	0	22	21
EPS Growth (%)		-1219.4%	0.0%	-156.4%	-24.5%	-20.8%	21.6%	-45.4%	-206.4%
EPS Analysts (#)	0	0	0	0	0	0	21	20

Forward Estimate History

How the next-FY EPS and revenue estimates have drifted over time. One line per fiscal year – past lines end when that FY became current.

Forward revenue projection history by FY

Expenses

Year	Revenue ($)	Cost of Revenue ($)	R&D ($)	SG&A ($)	Facilities / D&A ($)
2022	$18.9B	$5.1B	$3.3B	$1.1B	$348.0M
2023	$6.8B	$4.1B	$4.8B	$1.5B	$621.0M
2024	$3.2B	$1.3B	$4.5B	$1.2B	$189.0M
2025	$1.9B	$653.0M	$3.1B	$1.0B	$215.0M
TTM	$2.2B	$1.5B	$2.9B	$979.0M	$235.0M

Year	Revenue Change (%)	Cost of Revenue Change (%)	R&D Change (%)	SG&A Change (%)	Facilities / D&A Change (%)
2023	-64.22	-19.65	47.04	36.84	78.45
2024	-52.64	-68.69	-6.23	-24.21	-69.57
2025	-39.92	-48.78	-31.06	-13.29	13.76
TTM	14.67	129.40	-6.61	-3.83	9.30

No unmapped expenses.

Segment Performance

axis1_MRNA_Collaboration_Arrangement_Including_Arrangements_With_Affiliate.png

SEGMENTS v2025-09-09 · 2026-05-29 09:11 UTC — Units: $B. Rows list fiscal years (last 3 + TTM) with revenue for each segment; the final row shows the TTM revenue mix (operating income columns display “—” where mix is not applicable).

Year	Product Sales Rev	C O V I D19 Rev	Product And Service Other Rev	Grant Rev	Collaboration Arrangement Including Arrangements With Affiliate Rev	R S V Rev	License And Royalty Rev	Stand Ready Manufacturing Revenue Rev	Total Rev
2023	33.4B	6.67B	0.35B	0.28B	0.25B	–	–	–	40.9B
2024	15.5B	3.08B	0.28B	0.11B	0.14B	0.03B	0.04B	–	19.2B
2025	9.09B	1.81B	0.25B	0.07B	0.04B	0.01B	0.01B	0.08B	11.4B
TTM	26.8B	5.32B	0.62B	0.46B	0.19B	0.04B	–	–	33.5B
% of Total (TTM)	80.2%	15.9%	1.9%	1.4%	0.6%	0.1%	–	–	100%